SPRING HOUSE, Pa., Oct. 15, 2013 /PRNewswire/ -- Clinlogix, a global clinical research organization (CRO), has expanded its geographic reach with the acquisition of ikfe CRO GmbH, a CRO headquartered in Mainz, Germany that serves the European market.
Clinlogix has pioneered the use of innovative business practices and technologies and delivered individualized clinical research solutions to the biopharmaceutical and medical device industries for almost 25 years. The company's comprehensive services support the clinical development of medical devices, pharmaceuticals, biologics and diagnostics throughout the development lifecycle–from early feasibility/discovery through first-in-human, feasibility, pivotal and post-market clinical studies, and it has broad expertise in addressing regional and worldwide regulatory requirements.
JeanMarie Markham, CEO of Clinlogix, commented, "Our flexible business model focuses on innovation, integration and execution to drive operational excellence and efficiency. It has supported our rapid growth in the US, Latin America and nowEurope. Ikfe CRO is a high quality acquisition that provides us with the personnel, relationships and infrastructure to bring our unique service mix to clients on a worldwide basis."
Ms. Markham continued, "Our imaginative, individualized approach, integration of new technologies and reputation for cost-effective excellence have made us the go-to CRO for innovative medical device and biopharmaceutical companies. In today's increasingly demanding environment our distinctive model appeals to companies of all sizes, and we look forward to working with a wide range of life science companies to advance their new products in these important markets."
Dr. Marco Grenningloh, PhD, Chief Operating Officer and Managing Director of Clinlogix Europe, stated, "This acquisition greatly strengthens our strategic resources, knowledge base and infrastructure in the largest pharmaceutical market in the world. ikfe CRO was a highly respected regional service provider, and their specialized expertise and in-depth understanding are further enhancing our ability to provide knowledgeable, high quality services to our clients around the globe."
Clinlogix has experience in managing projects in Cardiovascular, Diabetes, CNS and Oncology, as well as a dozen other therapeutic specialties. The company's flexible business model allows clients to opt for full-service clinical development or separate functional services, depending on the client's needs.
From its base in Germany, Clinlogix Europe is a full service organization that supports the development of drugs, devices and diagnostics throughout Europe. It works in a variety of therapeutic areas but has special expertise in diabetes, cardiovascular disease and oncology.
Clinlogix is certified by the Women's Business Enterprise National Council and is a member of the Association of Clinical Research Organizations. Its German-based operations are certified according to DIN EN ISO 9001:2008.
Clinlogix is a global clinical research organization that has pioneered the use of innovative business practices and technologies and delivered individualized clinical research solutions to the medical device and biopharmaceutical industries for almost 25 years. Its comprehensive services support the clinical development of medical devices, pharmaceuticals, biologics and diagnostics from early feasibility/discovery through first-in-human, feasibility, pivotal and post-market clinical studies, and it has broad expertise in addressing regional and worldwide regulatory requirements. The company's flexible business model and reputation for excellence enable it to work with companies at all stages. Privately-held Clinlogix is headquartered in Spring House, PA. It has offices in the UK, Germany and Latin America. For more information, visit www.clinlogix.com.